no it’s not similar as the phase 2 had a single primary end point for inflammatory lesions. Now non inflammatory will be included as an endpoint which was the biggest home run of the lot in phase 2.
while inflammatory may be a 50/50 in phase 3, non inflammatory may just be the added element to take us through to market.
so happy with that after the outcomes of the past 6 months
Ann: BTX 1503 End of Phase 2 Milestone with FDA, page-16
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
-0.005(1.32%) |
Mkt cap ! $680.2M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 37.0¢ | $1.434M | 3.824M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 341679 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 300749 | 10 |
View Market Depth
| Last trade - 11.47am 04/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |